Taking stock of the drug industry, from the lab to the medicine chestOctober 27, 2023Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Kristoffer Tripplaar/Sipa via AP Images STAT+ | Why Sanofi got shellacked The Paris-based drug giant used a quarterly earnings announcement to make what appears to be a major strategic change. By Matthew Herper STAT+ | In major test for prime editing, scientists successfully correct mutations in monkeys The David Liu company says its results with prime editing, the CRISPR-based technology, shows its potential to treat numerous diseases. By Jason Mast STAT+ | FDA approves Lilly ulcerative colitis treatment with a new approach to tamping down inflammation Lilly had hoped for approval of Omvoh earlier in the year, but the FDA rejected the drug in April, citing issues around its manufacturing. By Jonathan Wosen STEFANI REYNOLDS/POOL/AFP via Getty Images STAT+ | ALS patients support bill that could help patients with other rare diseases Sen. Mike Braun held a hearing on a bill that would allow provisional approvals of investigational treatments for rare, incurable diseases. By John Wilkerson STAT+ | Up and Down the Ladder: The latest comings and goings From new hires to departures, transfers and promotions, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments